Moss, R B, Mercandetti, A, Vojdani, A · Journal of clinical immunology · 1999 · DOI
This study looked at whether a molecule called TNF-alpha, which helps control inflammation in the body, is elevated in people with ME/CFS. Researchers compared blood levels of TNF-alpha in patients with ME/CFS to healthy people without the condition. They found that people with ME/CFS had significantly higher levels of TNF-alpha, suggesting that inflammation may play a role in the disease.
This early immunological research provided foundational evidence that ME/CFS may involve dysregulated inflammatory pathways, shifting the understanding of the disease beyond purely psychiatric explanations. The findings suggested potential therapeutic targets, such as TNF-alpha blockers, which could open new treatment avenues for patients with limited current options.
This study does not prove that TNF-alpha elevation causes ME/CFS—only that an association exists. It does not establish whether elevated TNF-alpha is a primary driver of symptoms, a secondary effect of the disease process, or a biomarker of disease state. The cross-sectional design cannot determine causation or identify optimal therapeutic targets without further research.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.